• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Immuron Limited

    7/3/24 6:10:46 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMRN alert in real time by email
    6-K 1 ea0208797-6k_immuron.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of July 2024

     

    Commission File Number: 001-38104

     

    IMMURON LIMITED

    (Name of Registrant)

     

    Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒     Form 40-F ☐

     

    Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

     

    Yes ☐     No ☒

     

    If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

     

     

     

     

     

      

    INCORPORATION BY REFERENCE

     

    This report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (No. 333-280667) filed on July 2, 2024 (the “Registration Statement”) of Immuron Limited (the “Company”) (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Entry into At The Market Offering Agreement with H.C. Wainwright & Co., LLC

     

    On July 2, 2024, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, ADSs having an aggregate offering price of up to $2,069,083 through H.C. Wainwright as its sales agent; provided, however, that the Company will not issue or sell more than 854,993 ADSs. The offer and sale, if any, of the ADSs by the Company under the ATM Agreement is subject to the effectiveness of the Registration Statement.

     

    H.C. Wainwright may sell the ADSs by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the ADSs. H.C. Wainwright will use commercially reasonable efforts to sell the ADSs from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay H.C. Wainwright a commission equal to three percent (3.0%) of the gross sales proceeds of any ADSs sold through H.C. Wainwright under the ATM Agreement, and also has provided H.C. Wainwright with customary indemnification and contribution rights.

     

    The Company is not obligated to make any sales of ADSs under the ATM Agreement. The Company or H.C. Wainwright may suspend or terminate the offering of ADSs upon notice to the other party and subject to other conditions. H.C. Wainwright will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of the Nasdaq Stock Market.

     

    The foregoing description of the ATM Agreement is not complete and is qualified in its entirety by reference to the full text of the ATM Agreement, a copy of which is filed herewith as Exhibit 1.1 to this report on Form 6-K and is incorporated herein by reference. A copy of the legal opinion of Francis Abourizk Lightowlers, the Company’s Australian counsel, relating to the underlying ordinary shares issued in connection with the ATM Agreement is attached as Exhibit 5.1 hereto.

     

    This report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

     

    1

     

     

    EXHIBIT INDEX

     

    Exhibit
    Number
      Description
    1.1   At The Market Offering Agreement, dated as of July 2, 2024, by and between Immuron Limited and H.C. Wainwright & Co., LLC.
    5.1   Opinion of Francis Abourizk Lightowlers
    23.1   Consent of Francis Abourizk Lightowlers (included in Exhibit 5.1)

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      IMMURON LIMITED
         
    Date: July 2, 2024 By: /s/ Phillip Hains
        Phillip Hains
        Company Secretary

     

     

    3

     

     

    Get the next $IMRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMRN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream

    MIAMI, Jan. 21, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - Presenting Today - January 21, 2026 8:45Virtual Lobby opens.Register for the Conference. If you alread

    1/21/26 7:00:00 AM ET
    $CLNN
    $DEVS
    $DGXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance/Investors Services
    Finance

    Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream

    MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayJanuary 21, 2026 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

    1/20/26 7:00:00 AM ET
    $CLNN
    $DEVS
    $DGXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance/Investors Services
    Finance

    Immuron Reports Continued Sales Growth

    Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp)Q2 sales AUD$2.2 million up 11% on prior quarter Australia H1 sales AUD$3.3 million up 13% on prior comparative period (pcp)Q2 sales AUD$1.7 million up 11% on prior quarterAustralian launch of ProIBS® Canada H1 sales AUD$56 thousand down 85% on prior comparative period (pcp)Q2 sales AUD$42 thousand up 191% on prior quarter USA H1 sales AUD$0.9 million up 17% on prior comparative period (pcp)Q2 sales AUD$0.4 million up 8% on prior quarter MELBOURNE, Australia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integra

    1/19/26 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRN
    SEC Filings

    View All

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    1/22/26 9:58:42 PM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    1/20/26 7:01:24 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    1/14/26 8:00:05 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRN
    Leadership Updates

    Live Leadership Updates

    View All

    Immuron Board Changes

    MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. Immuron over the past few years has been ongoing with significant positive change. We have accelerated our commercial activities through higher level of marketing, improved channel management and strategic intent. Our scientific endeavours are bearing results with strong clinical data supporting IMC's unique hyper-immune colos

    5/31/24 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer

    MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Steven Lydeamore as Chief Executive Officer (CEO) of the Company effective 27 June 2022. Mr. Lydeamore has 30 years international pharmaceutical experience, working in Australia, Canada and USA. Mr. Lydeamore brings valuable international experience having spent eleven years working at Canadian global pharmaceutical company Apotex Inc., and four years for Mayne Pharma (USA) Limited. This i

    5/5/22 8:22:54 PM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appointment of Paul Brennan as Non-Executive Director

    MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Paul Brennan as an independent Non-Executive Director of the Company with effect from today. Mr Brennan has extensive experience in the health system through his clinical background and commercial exposure with various multinational companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo Limited (ASX:PNV) for 7 years from 2015 to 2021 and took the company from $30M to a high

    3/16/22 9:30:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care